Skip to content Skip to footer
Subscribe Now
AbbVie & Xilio Therapeutics
NEWS

AbbVie Collaborates with Xilio Therapeutics to Develop Next-Generation Tumor-Activated Immunotherapies

Shots:AbbVie & Xilio have entered into a collaboration & option-to-license agreement to leverage Xilio's proprietary tech for developing tumor-activated Abs As per the deal, Xilio will get $52M upfront (incl. $10M equity investment), & is entitled to receive ~$2.1B in contingent payments for option-related fees, milestones, & tiered royalties Xilio’s platform develops…
February 13, 2025

Read more

Spotlight Interview_David A. Dodd
SPOTLIGHT

Spotlight Interview: David A. Dodd, CEO at GeoVax Labs, in an Engaging Conversation with PharmaShots

PharmaShots’ Spotlight offers a unique platform for biopharma, life sciences, and healthcare companies, allowing them to connect with their target audiences and like-minded people. This week at the Spotlight, we had a riveting discussion with David A. Dodd, Chairman, President & CEO, at GeoVax Labs. David eloquently highlighted GeoVax’s extraordinary journey over the years from…
February 26, 2024

Read more

PharmaShots Interview In Conversation with Portage’s CEO and Director, Dr. Ian Walters, Where he Shares Insights on Ongoing Clinical-Stage and Development Programs
VIEWPOINTS

PharmaShots Interview: In Conversation with Portage’s CEO and Director, Dr. Ian Walters, Where he Shares Insights on Ongoing Clinical-Stage and Development Programs

Shots:Ian spoke about the study design of the clinical trials of its lead iNKT agonistsHe also emphasized the advancement of novel immunotherapies through new collaborations The interview provides a gist of Portage's development plan for its pipeline and various options to improve cancer treatmentSmriti: Explain the details (MOA, ROA, formulations, etc.) of PORT-2 & PORT-3?…
June 8, 2022

Read more